Xatral ER
Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
Tabia za bidhaa
(SPC)
27-05-2024
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
Alfuzosin hydrochloride
Inapatikana kutoka:
Sanofi-Aventis Australia Pty Ltd
Darasa:
Medicine Registered
Tabia za bidhaa
PRODUCT INFORMATION
May 2013
Xatral and Xatral ER - alfuzosin hydrochloride
xatral-xatral-er-ccdsv10-piv8-28may13
Page
1
PRODUCT INFORMATION
XATRAL
®
AND XATRAL
®
ER
NAME OF MEDICINE
AUSTRALIAN APPROVED NAME
Alfuzosin hydrochloride
CHEMICAL STRUCTURE
Molecular Formula:
Molecular Weight: 425.9
Chemical Name: (+,-)
N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl) methylamino] propyl]
tetrahydro-2-furancarboxamide hydrochloride
CAS REGISTRY NUMBER
81403-68-1
DESCRIPTION
Xatral (alfuzosin hydrochloride) is an
orally active quinazoline derivative.
Alfuzosin hydrochloride is a white to
off white crystalline powder. It is freely soluble
in water.
N
N
CH
3
O
CH
3
O
NH
2
N
CH
3
NH
O
O
.HCl
PRODUCT INFORMATION
May 2013
Xatral and Xatral ER - alfuzosin hydrochloride
xatral-xatral-er-ccdsv10-piv8-28may13
Page
2
The 2.5mg immediate release tablets are white, round and
film-coated and each tablet contains
2.5mg of alfuzosin
hydrochloride as the active ingredient and lactose, microcrystalline cellulose,
povidone, sodium starch glycollate,
magnesium stearate as excipients; Coating: hypromellose,
macrogol 400 and titanium dioxide.
The
5.0mg extended release tablets are a pale-yellow colour, round and film-coated and each
tablet contains 5.0mg of alfuzosin
hydrochloride as the active ingredient with microcrystalline
Soma hati kamili
